By otakuyassine3@gmail.com 
Cibc World Markets Corp acquired a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 17,683 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the last quarter. Geode Capital Management LLC grew its stake in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares during the last quarter. State Street Corp increased its position in Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares during the period. JPMorgan Chase & Co. lifted its stake in Esperion Therapeutics by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after buying an additional 19,588 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Esperion Therapeutics by 31.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 220,730 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.
Esperion Therapeutics Price Performance
ESPR opened at $1.50 on Friday. The business has a 50 day moving average price of $1.78 and a two-hundred day moving average price of $2.07. The company has a market capitalization of $296.77 million, a price-to-earnings ratio of -2.34 and a beta of 1.04. Esperion Therapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $3.94.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Thursday, March 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.75.
View Our Latest Stock Report on Esperion Therapeutics
Esperion Therapeutics Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Articles
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report).
Receive News & Ratings for Esperion Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Esperion Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.